BPG is committed to discovery and dissemination of knowledge
Featured Articles
3/27/2024 1:51:18 PM | Browse: 106 | Download: 131
Publication Name World Journal of Hepatology
Manuscript ID 91355
Country India
2023-12-27 13:10
Peer-Review Started
2023-12-27 13:10
To Make the First Decision
Return for Revision
2024-01-13 16:42
2024-01-24 15:11
Second Decision
2024-03-04 02:52
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2024-03-04 06:32
Articles in Press
2024-03-04 06:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
2024-03-01 12:48
Typeset the Manuscript
2024-03-13 03:29
Publish the Manuscript Online
2024-03-27 13:28
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status
Manuscript Source Invited Manuscript
All Author List Tarana Gupta and Nikhil Sai Jarpula
Funding Agency and Grant Number
Corresponding Author Tarana Gupta, MBBS, MD, Professor, Researcher, Division of Hepatology, Department of Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, House No. 1065A Sector 1, Rohtak 124001, Haryana, India. taranagupta@gmail.com
Key Words Hepatocellular carcinoma; Tumour immune microenvironment; Immune checkpoint inhibitor; Atezolizumab; Bevacizumab; Pembrolizumab
Core Tip Hepatocellular carcinoma (HCC) is a prototype of inflammation associated cancer. Its varied etiology from viral to alcohol and non-alcoholic steatohepatitis, tumor extent, intrahepatic spread, vascular invasion and metastases along with underlying severity of liver dysfunction make it a complex scenario for adequate management. The recent elaboration of tumor microenvironment revealing immunogenic milieu and bringing the concept of “Cold” and “Hot” tumor opened the way for evaluation of immunotherapy in HCC. In recent years, with use of immune checkpoint inhibitors, there is a paradigm shift in management of advanced and unresectable HCC. With use of combination regime including immune checkpoint inhibitors and trans arterial chemoembolization/ablation/tyrosine kinase inhibitors, there is an ongoing effort at improving disease outcomes and minimizing the adverse events.
Publish Date 2024-03-27 13:28
Citation Gupta T, Jarpula NS. Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status. World J Hepatol 2024; 16 (3): 353-365
URL https://www.wjgnet.com/1948-5182/full/v16/i3/353.htm
DOI https://dx.doi.org/10.4254/wjh.v16.i3.353
Full Article (PDF) WJH-16-353-with-cover.pdf
Manuscript File 91355_Auto_Edited-JRF-Webster J-YJP.docx
Answering Reviewers 91355-Answering reviewers.pdf
Audio Core Tip 91355-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 91355-Conflict-of-interest statement.pdf
Copyright License Agreement 91355-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 91355-Language certificate.pdf
Peer-review Report 91355-Peer-review(s).pdf
Scientific Misconduct Check 91355-Bing-Fan JR-2.png
Scientific Editor Work List 91355-Scientific editor work list.pdf